The 18th annual ‘Improving Outcomes in the Treatment of Opioid Dependence’ (IOTOD) meeting took place as a virtual event on the 24–25 September 2020.
The 2020 IOTOD Scientific Committee led an engaging two-day meeting, featuring international field experts speaking on multiple and emerging topics, such as: opioid analgesic dependence (OAD) and chronic pain; opioid substitution therapy adherence and the real significance; destigmatising drug use in key populations; the experience so far with long-acting buprenorphine formulations (and their use during COVID-19); different stakeholder perspectives surrounding drug use; and best approaches to address HCV/HBV in PWIDs. The webcasts from this conference will be available to view on the IOTOD 2021 conference platform once you have registered for the event.
Faculty
Professor Gabriele Fischer
Addictions Clinic Medical Director, Medical University of Vienna
Vienna, Austria
Professor Nicholas Lintzeris
Director, Community Based Treatment Interventions, Drug & Alcohol Services South Australia
Sydney, Australia
Professor Heino Stöver
Professor of Social Scientific Addiction Research, Frankfurt University of Applied Sciences
Frankfurt, Germany
Dr Arun Bhaskar
Hon Consultant, Pain Management Centre, Charing Cross Hospital, Imperial College NHS Trust
London, UK
Dr Michael Kelleher
Consultant Addictions Psychiatrist, South London and Maudsley NHS Foundation Trust
London, UK
Professor Graham Foster
Professor of Hepatology, Queen Mary's University of London & Consultant, Bart's Health NHS Trust
London, UK
Professor Ashley Brown
Consultant Hepatologist, St. Mary’s and Hammersmith Hospitals, and Professor of Practice (Viral Hepatitis), Imperial College London
London, UK
Sponsors
The 2020 IOTOD conference is supported by the following companies:
Camurus
Camurus is a Swedish research-based pharmaceutical company with more than 25 years of innovation and leadership in lipid-based drug delivery technologies. For the development of new product candidates, Camurus utilises its own patented FluidCrystal® drug delivery technologies. New proprietary medicines with improved properties and better treatment outcomes are developed by combining these technologies with established and regulatory approved active ingredients. Camurus’ development pipeline contains product candidates that address conditions with distinct and important medical needs, such as cancer, endocrine disorders, metabolic disorders, opioid dependence and chronic pain.
Gilead Sciences
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.
AbbVie
AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world’s most complex and critical conditions. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world.
Session Sponsors
Indivior
